Analyst downgrades typically lead to a negative perception among investors and can result in short-term stock price declines. The downgrade from Outperform to Peer Perform suggests that Wolfe Research no longer sees Agilon Health outperforming its peers, which could lead to reduced investor confidence and a potential decrease in stock price.